Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Receivables Refunds (2021 - 2026)

Indivior Pharmaceuticals has reported Receivables Refunds over the past 6 years, most recently at $12.0 million for Q1 2026.

  • For Q1 2026, Receivables Refunds fell 58.62% year-over-year to $12.0 million; the TTM value through Mar 2026 reached $12.0 million, down 58.62%, while the annual FY2025 figure was $2.0 million, 93.94% down from the prior year.
  • Receivables Refunds for Q1 2026 was $12.0 million at Indivior Pharmaceuticals, up from $2.0 million in the prior quarter.
  • Over five years, Receivables Refunds peaked at $33.0 million in Q4 2024 and troughed at $2.0 million in Q4 2025.
  • A 5-year average of $14.6 million and a median of $12.5 million in 2025 define the central range for Receivables Refunds.
  • On a YoY basis, Receivables Refunds climbed as much as 222.22% in 2025 and fell as far as 93.94% in 2025.
  • Year by year, Receivables Refunds stood at $5.0 million in 2022, then skyrocketed by 220.0% to $16.0 million in 2023, then surged by 106.25% to $33.0 million in 2024, then crashed by 93.94% to $2.0 million in 2025, then soared by 500.0% to $12.0 million in 2026.
  • Business Quant data shows Receivables Refunds for INDV at $12.0 million in Q1 2026, $2.0 million in Q4 2025, and $13.0 million in Q3 2025.